Successful three-year levofloxacin treatment for recurrent non-typhoidal Salmonella bacteremia in a patient with a bioprosthetic valve
Abstract
Although uncommon, non-typhoidal Salmonella bacteremia is clinically challenging, especially in patients with prosthetic material. Infective endocarditis can occur as a complication of non-typhoidal Salmonella bacteremia, and management typically involves a six-week course of antibiotics in conjunction with surgery. However, the optimal management for patients with retained prosthetic material in the absence of a clear infectious focus remains uncertain. We report a case of recurrent non-typhoidal Salmonella bacteremia in a patient with a bioprosthetic valve. Imaging studies revealed no identifiable infectious focus. Initial two episodes were treated with ceftriaxone; the third was managed with levofloxacin and rifampin, followed by three years of levofloxacin. The patient was cured without surgery. This case highlights the therapeutic challenges of managing non-typhoidal Salmonella bacteremia in the presence of prosthetic material. In cases where extensive imaging studies reveal no infectious focus, long-term antimicrobial therapy without surgical intervention may be a feasible approach, provided that persistent negativity of blood cultures and clinical stability are achieved. Such cases may also enable clinicians to determine the appropriate timing of discontinuing long-term oral antimicrobial therapy. • Challenging recurrent non-typhoidal Salmonella bacteremia with prosthetic material • Suspected biofilm-related infection with no focus detected on imaging • Successful…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.